Replies to post #209564 on Cytodyn Inc (CYDY)

[C-20]

We know about the trials and everything else we also know we have top line NASH results coming up and some type of partnership that will help with trials and funding. That’s exactly what we plan to do is carry on. We also understand without these things we can’t move forward.

[The Dark KnaDDir]

Yep, also looks like the market was not impressed by the mTNBC data presented at ASCO. The facts remain that zero revenue is coming in and millions are owed to Samsung and Amarex with no way to pay them. Of course, the SEC and DOJ investigations are still looming and there is a disclaimer at the top of every page on cytodyn's website:

On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab. Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication. For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.